Follicular lymphomas

Critical Reviews in Oncology/Hematology

Volumn 66, Issue 3, 2008, Pages 248-261

  Vitolo, Umberto ^a   Ferreri, Andrés J M ^b   Montoto, Silvia ^c  

^a MOLINETTE HOSPITAL   (Italy)

^b Medical Oncology Unit   (Italy)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

bcl 2; FLIPI; Follicular lymphoma; rituximab; t(14 ; 18)

Indexed keywords

ALPHA2B INTERFERON; ANTISENSE OLIGODEOXYNUCLEOTIDE; BLEOMYCIN; CANCER VACCINE; CD23 ANTIGEN; CD5 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GLYCOPROTEIN P 15095; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERFERON; LEUKOSIALIN; METHOTREXATE; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; TENIPOSIDE; TOSITUMOMAB; VINCRISTINE;

ANTIGEN EXPRESSION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CARCINOGENESIS; CLINICAL FEATURE; CYTOGENETICS; FOLLICULAR LYMPHOMA; HUMAN; IMMUNOPHENOTYPING; LACTATE DEHYDROGENASE BLOOD LEVEL; MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; PROGNOSIS; RADIOIMMUNOTHERAPY; REVIEW; TREATMENT PLANNING; WATCHFUL WAITING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY; INCIDENCE; LYMPHOMA, FOLLICULAR; NEOPLASM STAGING; RISK FACTORS;

EID: 43049101601     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.01.014     Document Type: Review

References (144)

1. Banks P.M. Incorporation of immunostaining data in anatomic pathology reports. Am J Surg Pathol 16 (1992) 808
2. Lennert K. Malignant lymphomas: other than Hodgkin's disease: histology, cytology, ultrastructure, immunology (1978), Springer-Verlag Book, Berlin
3. Harris N.L., Jaffe E.S., Stein H., et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84 (1994) 1361-1392
4. Harris N.L., Jaffe E.S., Diebold J., et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17 (1999) 3835-3849
5. Jaffe E.S., Shevach E.M., Frank M.M., Berard C.W., and Green I. Nodular lymphoma-evidence for origin from follicular B lymphocytes. N Engl J Med 290 (1974) 813-819
6. Ngan B.Y., Warnke R.A., Wilson M., et al. Monocytoid B-cell lymphoma: a study of 36 cases. Hum Pathol 22 (1991) 409-421
7. Stein R.S., Magee M.J., Lenox R.K., et al. Malignant lymphomas of follicular center cell origin in man. VI. Large cleaved cell lymphoma. Cancer 60 (1987) 2704-2711
8. Mann R.B., and Berard C.W. Criteria for the cytologic subclassification of follicular lymphomas: a proposed alternative method. Hematol Oncol 1 (1983) 187-192
9. Ngan B.Y., Chen-Levy Z., Weiss L.M., Warnke R.A., and Cleary M.L. Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation. N Engl J Med 318 (1988) 1638-1644
10. Pezzella F., Tse A.G., Cordell J.L., et al. Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am J Pathol 137 (1990) 225-232
11. Yunis J.J., Frizzera G., Oken M.M., et al. Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer. N Engl J Med 316 (1987) 79-84
12. Bakhshi A., Jensen J.P., Goldman P., et al. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 41 (1985) 899-906
13. Cleary M.L., Smith S.D., and Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell 47 (1986) 19-28
14. Hockenbery D.M., Zutter M., Hickey W., Nahm M., and Korsmeyer S.J. BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 88 (1991) 6961-6965
15. McDonnell T.J., Deane N., Platt F.M., et al. bcl-2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 57 (1989) 79-88
16. Tsujimoto Y., Cossman J., Jaffe E., and Croce C.M. Involvement of the bcl-2 gene in human follicular lymphoma. Science 228 (1985) 1440-1443
17. Kuppers R., Klein U., Hansmann M.L., and Rajewsky K. Cellular origin of human B-cell lymphomas. N Engl J Med 341 (1999) 1520-1529
18. Limpens J., de Jong D., van Krieken J.H., et al. Bcl-2/JH rearrangements in benign lymphoid tissues with follicular hyperplasia. Oncogene 6 (1991) 2271-2276
19. Summers K.E., Goff L.K., Wilson A.G., et al. Frequency of the Bcl-2/IgH rearrangement in normal individuals: implications for the monitoring of disease in patients with follicular lymphoma. J Clin Oncol 19 (2001) 420-424
20. Gallagher C.J., Gregory W.M., Jones A.E., et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 4 (1986) 1470-1480
21. Armitage J.O., and Weisenburger D.D. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 16 (1998) 2780-2795
22. Bastion Y., Berger F., Bryon P.A., et al. Follicular lymphomas: assessment of prognostic factors in 127 patients followed for 10 years. Ann Oncol 2 Suppl. 2 (1991) 123-129
23. Longo D.L., DeVita Jr. V.T., Duffey P.L., et al. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. J Clin Oncol 9 (1991) 25-38
24. Horning S.J., and Rosenberg S.A. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 311 (1984) 1471-1475
25. Garvin A.J., Simon R.M., Osborne C.K., et al. An autopsy study of histologic progression in non-Hodgkin's lymphomas. 192 cases from the National Cancer Institute. Cancer 52 (1983) 393-398
26. Risdall R., Hoppe R.T., and Warnke R. Non-Hodgkin's lymphoma: a study of the evolution of the disease based upon 92 autopsied cases. Cancer 44 (1979) 529-542
27. O'Brien M.E., Easterbrook P., Powell J., et al. The natural history of low grade non-Hodgkin's lymphoma and the impact of a no initial treatment policy on survival. Q J Med 80 (1991) 651-660
28. Yuen A.R., Kamel O.W., Halpern J., and Horning S.J. Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol 13 (1995) 1726-1733
29. Montoto S., Davies A.J., Matthews J., et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 25 (2007) 2426-2433
30. Carbone P.P., Kaplan H.S., Musshoff K., Smithers D.W., and Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 31 (1971) 1860-1861
31. Alt F.W., Blackwell T.K., and Yancopoulos G.D. Development of the primary antibody repertoire. Science 238 (1987) 1079-1087
32. Lopez-Guillermo A., Cabanillas F., McLaughlin P., et al. The clinical significance of molecular response in indolent follicular lymphomas. Blood 91 (1998) 2955-2960
33. Czuczman M.S., Weaver R., Alkuzweny B., Berlfein J., and Grillo-Lopez A.J. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 22 (2004) 4711-4716
34. Rambaldi A., Carlotti E., Oldani E., et al. Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma. Blood 105 (2005) 3428-3433
35. Freedman A.S., Neuberg D., Mauch P., et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 94 (1999) 3325-3333
36. Johnson P.W., Rohatiner A.Z., Whelan J.S., et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 13 (1995) 140-147
37. Soubeyran P., Eghbali H., Bonichon F., et al. Low-grade follicular lymphomas: analysis of prognosis in a series of 281 patients. Eur J Cancer 27 (1991) 1606-1613
38. Leonard R.C., Hayward R.L., Prescott R.J., and Wang J.X. The identification of discrete prognostic groups in low grade non-Hodgkin's lymphoma. The Scotland and Newcastle Lymphoma Group Therapy Working Party. Ann Oncol 2 (1991) 655-662
39. Brice P., Bastion Y., Lepage E., et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 15 (1997) 1110-1117
40. Solal-Celigny P., Lepage E., Brousse N., et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol 16 (1998) 2332-2338
41. The GOELAMS Group, France, Foussard C., Desablens B., Sensebe L., et al. Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? Applicability to stage III-IV patients. Ann Oncol 8 Suppl. 1 (1997) 49-52
42. Lopez-Guillermo A., Montserrat E., Bosch F., et al. Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 12 (1994) 1343-1348
43. Decaudin D., Lepage E., Brousse N., et al. Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients-a study of the groupe d'Etude des lymphomes de l'Adulte. J Clin Oncol 17 (1999) 2499-2505
44. Rodriguez J., McLaughlin P., Hagemeister F.B., et al. Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features. Blood 93 (1999) 2202-2207
45. Denham J.W., Denham E., Dear K.B., and Hudson G.V. The follicular non-Hodgkin's lymphomas. II. Prognostic factors: what do they mean?. Eur J Cancer 32A (1996) 480-490
46. Voso M.T., Pantel G., Weis M., et al. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. Br J Haematol 109 (2000) 729-735
47. Ladetto M., Corradini P., Vallet S., et al. High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood 100 (2002) 1559-1565
48. Apostolidis J., Gupta R.K., Grenzelias D., et al. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol 18 (2000) 527-536
49. Tilly H., Rossi A., Stamatoullas A., et al. Prognostic value of chromosomal abnormalities in follicular lymphoma. Blood 84 (1994) 1043-1049
50. Klapper W., Hoster E., Rolver L., et al. Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group. J Clin Oncol 25 (2007) 3330-3336
51. Bastion Y., Sebban C., Berger F., et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 15 (1997) 1587-1594
52. Lo Coco F., Gaidano G., Louie D.C., et al. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 82 (1993) 2289-2295
53. Sander C.A., Yano T., Clark H.M., et al. p53 mutation is associated with progression in follicular lymphomas. Blood 82 (1993) 1994-2004
54. Yano T., Jaffe E.S., Longo D.L., and Raffeld M. MYC rearrangements in histologically progressed follicular lymphomas. Blood 80 (1992) 758-767
55. Dreyling M.H., Roulston D., Bohlander S.K., Vardiman J., and Olopade O.I. Codeletion of CDKN2 and MTAP genes in a subset of non-Hodgkin's lymphoma may be associated with histologic transformation from low-grade to diffuse large-cell lymphoma. Genes Chromosomes Cancer 22 (1998) 72-78
56. Elenitoba-Johnson K.S., Gascoyne R.D., Lim M.S., et al. Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood 91 (1998) 4677-4685
57. Pinyol M., Cobo F., Bea S., et al. p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood 91 (1998) 2977-2984
58. Federico M., Vitolo U., Zinzani P.L., et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood 95 (2000) 783-789
59. Solal-Celigny P., Roy P., Colombat P., et al. Follicular lymphoma international prognostic index. Blood 104 (2004) 1258-1265
60. Perea G., Altes A., Montoto S., et al. Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems. Ann Oncol 16 (2005) 1508-1513
61. Young R.C., Longo D.L., Glatstein E., et al. The treatment of indolent lymphomas: watchful waiting vs. aggressive combined modality treatment. Semin Hematol 25 (1988) 11-16
62. Ardeshna K.M., Smith P., Norton A., et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 362 (2003) 516-522
63. Besa P.C., McLaughlin P.W., Cox J.D., and Fuller L.M. Long term assessment of patterns of treatment failure and survival in patients with stage I or II follicular lymphoma. Cancer 75 (1995) 2361-2367
64. Pendlebury S., el Awadi M., Ashley S., Brada M., and Horwich A. Radiotherapy results in early stage low grade nodal non-Hodgkin's lymphoma. Radiother Oncol 36 (1995) 167-171
65. De Los Santos J.F., Mendenhall N.P., and Lynch Jr. J.W. Is comprehensive lymphatic irradiation for low-grade non-Hodgkin's lymphoma curative therapy? Long-term experience at a single institution. Int J Radiat Oncol Biol Phys 38 (1997) 3-8
66. Mac Manus M.P., and Hoppe R.T. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 14 (1996) 1282-1290
67. Petersen P.M., Gospodarowicz M., Tsang R., et al., Petersen P.M., Gospodarowicz M., Tsang R., et al. Long-term outcome in stage I and II follicular lymphoma following treatment with involved field radiation therapy alone. J Clin Oncol 22 14S (2004) 561
68. Advani R., Rosenberg S.A., and Horning S.J. Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy. J Clin Oncol 22 (2004) 1454-1459
69. Soubeyran P., Eghbali H., Trojani M., et al. Is there any place for a wait-and-see policy in stage I0 follicular lymphoma? A study of 43 consecutive patients in a single center. Ann Oncol 7 (1996) 713-718
70. McLaughlin P., Fuller L.M., Velasquez W.S., et al. Stage I-II follicular lymphoma. Treatment results for 76 patients. Cancer 58 (1986) 1596-1602
71. Carde P., Burgers J.M., van Glabbeke M., et al. Combined radiotherapy-chemotherapy for early stages non-Hodgkin's lymphoma: the 1975-1980 EORTC controlled lymphoma trial. Radiother Oncol 2 (1984) 301-312
72. Monfardini S., Banfi A., Bonadonna G., et al. Improved five year survival after combined radiotherapy-chemotherapy for stage I-II non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 6 (1980) 125-134
73. Kamath S.S., Marcus Jr. R.B., Lynch J.W., and Mendenhall N.P. The impact of radiotherapy dose and other treatment-related and clinical factors on in-field control in stage I and II non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 44 (1999) 563-568
74. Wilder R.B., Jones D., Tucker S.L., et al. Long-term results with radiotherapy for Stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys 51 (2001) 1219-1227
75. Seymour J.F., Pro B., Fuller L.M., et al. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. J Clin Oncol 21 (2003) 2115-2122
76. Jacobs J.P., Murray K.J., Schultz C.J., et al. Central lymphatic irradiation for stage III nodular malignant lymphoma: long-term results. J Clin Oncol 11 (1993) 233-238
77. Murtha A.D., Rupnow B.A., Hansosn J., Knox S.J., and Hoppe R. Long-term follow-up of patients with Stage III follicular lymphoma treated with primary radiotherapy at Stanford University. Int J Radiat Oncol Biol Phys 49 (2001) 3-15
78. Ezdinli E.Z., Anderson J.R., Melvin F., et al. Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma. J Clin Oncol 3 (1985) 769-775
79. Foran J.M., Rohatiner A.S., Norton A.J., Mathews J., Amess J.L., and Lister T.A. High-dose (HD) therapy with autologous hematopoietic support in patients with transformed follicular lymphoma (FL): a study of 27 patients (pts) from a single centre. Proc ASCO 16 (1997) A59 [meeting abstract]
80. Unterhalt M., Herrmann R., Tiemann M., et al. Prednimustine, mitoxantrone (PmM) vs. cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group. Leukemia 10 (1996) 836-843
81. Brandt L., Kimby E., Nygren P., and Glimelius B. A systematic overview of chemotherapy effects in indolent non-Hodgkin's lymphoma. Acta Oncol 40 (2001) 213-223
82. Peterson B.A., Petroni G.R., Frizzera G., et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. J Clin Oncol 21 (2003) 5-15
83. Dana B.W., Dahlberg S., Nathwani B.N., et al. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 11 (1993) 644-651
84. Barosi G., Carella A., Lazzarino M., et al. Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. Haematologica 90 (2005) 1236-1257
85. Coiffier B., Neidhardt-Berard E.M., Tilly H., et al. Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol 10 (1999) 1191-1197
86. Hagenbeek A., Eghbali H., Monfardini S., et al. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant non-Hodgkin's lymphoma. J Clin Oncol 24 (2006) 1590-1596
87. McLaughlin P., Hagemeister F.B., Romaguera J.E., et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 14 (1996) 1262-1268
88. Velasquez W.S., Lew D., Grogan T.M., et al. Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501. J Clin Oncol 21 (2003) 1996-2003
89. Zinzani P.L., Pulsoni A., Perrotti A., et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 22 (2004) 2654-2661
90. Allen I.E., Ross S.D., Borden S.P., et al. Meta-analysis to assess the efficacy of interferon-alpha in patients with follicular non-Hodgkin's lymphoma. J Immunother 24 (2001) 58-65
91. Rohatiner A.Z., Gregory W.M., Peterson B., et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 23 (2005) 2215-2223
92. Maloney D.G., Grillo-Lopez A.J., White C.A., et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90 (1997) 2188-2195
93. McLaughlin P., Grillo-Lopez A.J., Link B.K., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16 (1998) 2825-2833
94. Rambaldi A., Lazzari M., Manzoni C., et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 99 (2002) 856-862
95. Vitolo U., Boccomini C., Ladetto M., et al. A brief course of chemo-immunotherapy FND + rituximab is effective to induce a high clinical and molecular response in elderly patients with advanced stage follicular lymphoma (FL) at diagnosis. Blood 102 (2003) 400a
96. Czuczman M.S., Koryzna A., Mohr A., et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 23 (2005) 694-704
97. Marcus R., Imrie K., Belch A., et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105 (2005) 1417-1423
98. Hiddemann W., Kneba M., Dreyling M., et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106 (2005) 3725-3732
99. Herold M., Pasold R., Srock S., et al. Results of a prospective randomised open label phase III study comparing rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin's lymphoma (NHL) and mantle-cell-lymphoma (MCL). ASH (2004)
100. Salles G., Foussard C., Nicolas M., et al. Rituximab added to áIFN + CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: first analysis of the GELA-GOELAMS FL-2000 randomized trial in 359 patients. ASH 2004. ASH (2004) [Abstract 160]
101. Morel P., Laporte J.P., Noel M.P., et al. Autologous bone marrow transplantation as consolidation therapy may prolong remission in newly diagnosed high-risk follicular lymphoma: a pilot study of 34 cases. Leukemia 9 (1995) 576-582
102. Deconinck E., Foussard C., Milpied N., et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 105 (2005) 3817-3823
103. Lenz G., Dreyling M., Schiegnitz E., et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 104 (2004) 2667-2674
104. Sebban C., Mounier N., Brousse N., et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 108 (2006) 2540-2544
105. Piro L.D., White C.A., Grillo-Lopez A.J., et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 10 (1999) 655-661
106. Ghielmini M., Schmitz S.F., Cogliatti S.B., et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood 103 (2004) 4416-4423
107. Zinzani P.L., Bendandi M., Magagnoli M., et al. Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma. Ann Oncol 8 (1997) 379-383
108. Forstpointner R., Dreyling M., Repp R., et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104 (2004) 3064-3071
109. Rohatiner A.Z., Johnson P.W., Price C.G., et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 12 (1994) 1177-1184
110. Brice P., Simon D., Bouabdallah R., et al. High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol. Ann Oncol 11 (2000) 1585-1590
111. Sabloff M., Atkins H.L., ce-Bruckler I., et al. A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma. Biol Blood Marrow Transplant 13 (2007) 956-964
112. Schouten H.C., Qian W., Kvaloy S., et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 21 (2003) 3918-3927
113. Conde E., Insunza A., Lahuerta J.J., et al. Autologous stem cell transplantation (ASCT) in 419 patients with follicular lymphoma (FL). Blood (2002) 100
114. Vose J.M., Bierman P.J., Loberiza F.R., et al. Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index. Biol Blood Marrow Transplant 14 (2008) 36-42
115. Apostolidis J., Foran J.M., Johnson P.W., et al. Patterns of outcome following recurrence after myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma. J Clin Oncol 17 (1999) 216-221
116. Milligan D.W., Ruiz De Elvira M.C., Kolb H.J., et al. Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation. Br J Haematol 106 (1999) 1020-1026
117. Micallef I.N., Lillington D.M., Apostolidis J., et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 18 (2000) 947-955
118. Brown J.R., Yeckes H., Friedberg J.W., et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 23 (2005) 2208-2214
119. Gopal A.K., Gooley T.A., Maloney D.G., et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood 102 (2003) 2351-2357
120. Benekli M., Hahn T., Shafi F., et al. Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients. Bone Marrow Transplant 32 (2003) 139-143
121. Mandigers C.M., Raemaekers J.M., Schattenberg A.V., et al. Allogeneic bone marrow transplantation with T-cell-depleted marrow grafts for patients with poor-risk relapsed low-grade non-Hodgkin's lymphoma. Br J Haematol 100 (1998) 198-206
122. van Besien K., Sobocinski K.A., Rowlings P.A., et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 92 (1998) 1832-1836
123. van Besien K., Loberiza Jr. F.R., Bajorunaite R., et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 102 (2003) 3521-3529
124. Bierman P.J., Sweetenham J.W., Loberiza Jr. F.R., et al. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation-the Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol 21 (2003) 3744-3753
125. Perez-Simon J.A., Kottaridis P.D., Martino R., et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 100 (2002) 3121-3127
126. Khouri I.F., Saliba R.M., Giralt S.A., et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 98 (2001) 3595-3599
127. Robinson S.P., Goldstone A.H., Mackinnon S., et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 100 (2002) 4310-4316
128. Kaminski M.S., Estes J., Zasadny K.R., et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 96 (2000) 1259-1266
129. Witzig T.E., White C.A., Gordon L.I., et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 21 (2003) 1263-1270
130. Emmanouilides C., Witzig T.E., Molina A., et al. Improved safety and efficacy of yttrium-90 ibritumomab tiuxetan radioimmunotherapy when administered as 2nd or 3rd line therapy for relapsed low-grade, follicular, and transformed B-cell non-Hodgkin's lymphoma (NHL). Proc ASCO 22 (2003) 595
131. Gordon L.I., Witzig T.E., Murray J.L., et al. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with relapsed or refractory low grade, follicular or transformed B-cell NHL: Final results of a randomized controlled trial. Proc ASCO 23 (2004) 574
132. Emmanouilides C., Witzig T.E., White C.A., et al. Zevalin™ radioimmunotherapy is associated with a low infection risk. Blood 98 (2001) 228b
133. Bennett J.M., Kaminski M.S., Leonard J.P., et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood 105 (2005) 4576-4582
134. Williams C.D., Harrison C.N., Lister T.A., et al. High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. J Clin Oncol 19 (2001) 727-735
135. Cao T.M., Horning S., Negrin R.S., et al. High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience. Biol Blood Marrow Transplant 7 (2001) 294-301
136. Foran J.M., Apostolidis J., Papamichael D., et al. High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single centre. Ann Oncol 9 (1998) 865-869
137. van Besien K.W., Khouri I.F., Giralt S.A., et al. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management. J Clin Oncol 13 (1995) 1096-1102
138. Kaminski M.S., Zelenetz A.D., Press O.W., et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 19 (2001) 3918-3928
139. Macpherson N., Lesack D., Klasa R., et al. Small noncleaved, non-Burkitt's (Burkit-Like) lymphoma: cytogenetics predict outcome and reflect clinical presentation. J Clin Oncol 17 (1999) 1558-1567
140. Hawkins R.E., Zhu D., Ovecka M., et al. Idiotypic vaccination against human B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines. Blood 83 (1994) 3279-3288
141. Stevenson F.K., Zhu D., King C.A., et al. Idiotypic DNA vaccines against B-cell lymphoma. Immunol Rev 145 (1995) 211-228
142. Stevenson F.K., Zhu D., King C.A., et al. A genetic approach to idiotypic vaccination for B cell lymphoma. Ann NY Acad Sci 772 (1995) 212-226
143. Hsu F.J., Caspar C.B., Czerwinski D., et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood 89 (1997) 3129-3135
144. Webb A., Cunningham D., Cotter F., et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349 (1997) 1137-1141